Incyte Sets Date for First Quarter Fiscal 2002 Earnings Announcement PALO ALTO, CA, April 18, 2002 – Incyte Genomics, Inc. (Nasdaq: INCY), the leading genomic information company, announced today the intention to release its first quarter fiscal year 2002 earnings results on Wednesday, May 1, 2002 after the close of the stock market. Company management will host a conference call on Wednesday, May 1, 2002 at 2:00 p.m. PDT to discuss the company's results. The domestic dial in number for the conference call will be 800-231-5571 and the international dial in number will be 973-872-3462. A replay of the conference call will be available through May 7, 2002 (12:00 midnight PDT). The replay dial in number for both U.S. and International callers will be 973-341-3080 and the PIN number access code will be 3233857 A webcast will be distributed over CCBN's Investor Distribution Network to both institutional and individual investors. Individual investors can listen to the call through CCBN's individual investor center at www.companyboardroom.com or by visiting any of the investor sites in CCBN's Individual Investor Network such as America Online's Personal Finance Channel. Institutional investors can access the call via CCBN's password protected event management site, StreetEvents (http://www.streetevents.com). Incyte Genomics, Inc. has the largest commercial portfolio of issued United States patents covering human, full-length genes and the proteins they encode and is leveraging its leading intellectual property and genomic information position to be a leader in therapeutic small molecule, secreted protein and antibody discoveries. In addition, Incyte has also developed the leading integrated platform of genomic technologies designed to aid in the understanding of the molecular basis of disease. Incyte develops and markets genomic databases and licenses pharmaceutically relevant intellectual property. These offerings facilitate pharmaceutical and biotechnology researchers in their drug discovery and development; including gene discovery, understanding disease pathways, identifying new disease targets and the discovery and correlation of gene sequence variation to disease. Except for the historical information contained herein, the matters set forth in this press release, including without limitation statements as to the Company's intended earnings announcement date, Incyte's ability to leverage its intellectual property position to become a leader in therapeutic small molecule, secreted protein and antibody discoveries , and the ability of Incyte's product offerings to enhance the drug discovery and development efforts of its customers,are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including scheduling conflicts; the impact of competition and alternative technologies, processes and approaches on Incyte's business; Incyte's ability to compete against competitors that may have greater financial or other resources; changes in consumer demand for Incyte's product offerings ; changes in Incyte's business plan; Incyte's ability to obtain patent protection for its discoveries and to continue to be effective in expanding its patent coverage; and other risks detailed from time to time in Incyte's SEC reports, including its Annual Report on Form 10- K for the year ended December 31, 2001. Incyte disclaims any intent or obligation to update these forward-looking statements.